Company Long-Term Loans and Borrowings: NKGen (NKGN)

This chart of NKGen Biotech, Inc. (NKGN) stock quotes demonstrates the dynamics of a company developing innovative treatments for brain degeneration, where long-term debt stands at 0.00. The business relies on early-stage trial patents, creating an insurmountable barrier to entry for newcomers due to the complexity of biosynthesis. Growth is driven by breakthroughs in Alzheimer's and Parkinson's therapies, while strict FDA oversight and manufacturing complexities minimize external competition.

NKGen Biotech Inc (NKGN) Company Long-Term Debt: for the period 02/21/2024 - 03/15/2025

NKGen (NKGN) - metric breakdowns and financial figures

- market price and analyst price targets:
Stock Price nkgenbiotech.com|NKGN - Price Target Chart
- company stock exchange capitalization indicators:
Market Value NKGen Biotech|NKGN - Total Company Value
- book capitalization information:
Net Asset Value per Share NKGen Biotech|NKGN - Company Book Value|Capitalization to Book Value Ratio nkgenbiotech.com|NKGN - Aggregate Company Assets
- debt level and financial liquidity data:
Total Debt to Capital NKGen Biotech, Inc.|NKGN - Long-Term Debt to Capital|Short-Term Indebtedness to Equity NKGen Biotech Corp|NKGN - Company Aggregate Debts|Debts to Book Value NKGen Biotech|NKGN - Company Long-Term Debt|Company Short-Term Indebtedness NKGen Biotech|Intermediate Coverage Ratio nkgenbiotech.com
- earnings and market multiples details:
NKGN - Net Profit
Summary company analytics:NKGen Biotech, Inc.

NKGen Biotech, Inc. (NKGN) investments in robotic sterility systems are reflected in the trend of the issuer's long-term liabilities on the GURU.Markets platform. This indicator aggregates all creditor claims with a maturity of more than one year. It measures the financial leverage that enables the scaling of cell therapy production. Excessive debt increases interest expenses, while a deficit limits development. The balance of these factors determines the long-term sustainability of the business.

Competitors of NKGen Biotech, Inc. (NKGN)

Company Long-Term Debts biogen.com BIIB|NBIX - Company Long-Term Debt|Company Long-Term Loans and Borrowings RGC (Regencell Bioscience Ltd)|Axsome Therapeutics Inc (AXSM) - Company Long-Term Debt|Long-Term Debt ACADIA Corp (ACAD)|Company Long-Term Debt Xenon Pharmaceuticals|Company Long-Term Indebtedness VKTX (vikingtherapeutics.com)|Company Long-Term Debt Supernus (SUPN)|Company Long-Term Debts Catalyst Pharma (CPRX)|Company Long-Term Debts DNLI (Denali Therapeutics Inc)|Long-Term Indebtedness Harmony Corp|Biohaven Ltd. - Company Long-Term Debts|Long-Term Debt amylyx.com|Trevi Therapeutics, Inc. (TRVI) - Company Long-Term Debt|Company Long-Term Indebtedness PRAX|Company Long-Term Liabilities AVXL|CBLL: Company Long-Term Loans and Borrowings|Company Long-Term Debts PRTA|Company Long-Term Debt ALEC (alector.com)|Company Long-Term Debts ANNX (Annexon)|Long-Term Debt Volume Omeros Corp (OMER)|NGNE - Company Long-Term Debt|Long-Term Debt AC Immune Inc|VYGR (Voyager Therapeutics) - Company Long-Term Liabilities|NMRA: Amount of Long-Term Liabilities|SCLX (Scilex) - Company Long-Term Debts|Long-Term Debt Tevogen Bio Holdings Inc. TVGN|Company Long-Term Debts ACOG|Company Long-Term Liabilities cogrx.com CGTX|Company Long-Term Debts IKT (Inhibikase Therapeutics)|Company Long-Term Loans and Borrowings SAVA|ASRT: Company Long-Term Liabilities|Company Long-Term Loans and Borrowings COYA (Coya Therapeutics, Inc.)|VTGN: Company Long-Term Debts|OVID - Long-Term Debt Volume|Company Long-Term Debt Acumen Pharmaceuticals|Company Long-Term Indebtedness CRVO (cervomed.com)|Company Long-Term Debts ATHE|Company Long-Term Liabilities clene.com CLNN|PepGen - Company Long-Term Liabilities|Long-Term Debt Volume jupiterneurosciences.com (JUNS)|RLMD - Company Long-Term Debt|ANVS (annovisbio.com) - Company Long-Term Indebtedness|gracetx.com (GRCE) - Company Long-Term Debt|Firefly Neuroscience, Inc. (AIFF) - Company Long-Term Debts|KLTO (ANEW Medical) - Company Long-Term Debts|NRSN - Long-Term Indebtedness|Company Long-Term Debt Reviva Pharmaceuticals (RVPH)|metaviatx.com - Company Long-Term Indebtedness|Company Long-Term Debt NeurAxis NRXS|HSDT: Company Long-Term Indebtedness|Passage Bio Corp - Company Long-Term Debts|Long-Term Debt Neuphoria Therapeutics Inc.|NERV (Minerva Neurosciences) - Company Long-Term Liabilities|athira.com (ATHA) - Company Long-Term Debts|Company Long-Term Debt Addex Therapeutics Ltd|ALZN: Company Long-Term Loans and Borrowings|Company Long-Term Debt Cyclerion Therapeutics (CYCN)|PTIX - Long-Term Debt|Company Long-Term Debt Pasithea Therapeutics Corp. KTTA|CRGT: Company Long-Term Indebtedness|ATXI - Company Long-Term Debt|BCLI - Company Long-Term Debts|CARA: Company Long-Term Debts|Long-Term Indebtedness Chromocell CHRO|ELYM (Eliem Therapeutics, Inc.) - Company Long-Term Debts|Long-Term Debt Intra-Cellular ITCI|Company Long-Term Debt Longboard Pharmaceuticals, Inc. (LBPH)|Marinus Pharmaceuticals Inc - Company Long-Term Indebtedness|NeuroBo - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings SAGE|Synaptogenix, Inc. - Company Long-Term Debts|TRVN: Company Long-Term Debt|VIGL: Company Long-Term Debts|WENA - Long-Term Debt Volume|Company Long-Term Debt Cerevel